Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $1.25 target price on the biotechnology company’s stock. Chardan Capital’s price objective would indicate a potential upside of 75.73% from the company’s previous close.

MCRB has been the subject of a number of other reports. The Goldman Sachs Group decreased their price objective on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Stock Performance

NASDAQ:MCRB opened at $0.71 on Thursday. The company has a market cap of $123.84 million, a PE ratio of -3.09 and a beta of 2.19. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.53. The stock has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $0.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Avantax Advisory Services Inc. boosted its position in Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC lifted its position in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC lifted its position in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 44,461 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.